Cargando…
Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel
BACKGROUND: The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically. METHODS: We invited a group of experts k...
Autores principales: | Guzzi, Louis M., Bergler, Tobias, Binnall, Brian, Engelman, Daniel T., Forni, Lui, Germain, Michael J., Gluck, Eric, Göcze, Ivan, Joannidis, Michael, Koyner, Jay L., Reddy, V. Seenu, Rimmelé, Thomas, Ronco, Claudio, Textoris, Julien, Zarbock, Alexander, Kellum, John A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585126/ https://www.ncbi.nlm.nih.gov/pubmed/31221200 http://dx.doi.org/10.1186/s13054-019-2504-8 |
Ejemplares similares
-
Urine TIMP2 × IGFBP7 increases 24 hours before severe AKI
por: Ostermann, M, et al.
Publicado: (2014) -
Urinary Biomarkers TIMP-2 and IGFBP7 Early Predict Acute Kidney Injury after Major Surgery
por: Gocze, Ivan, et al.
Publicado: (2015) -
Urinary TIMP-2 and IGFBP7 as Early Biomarkers of Acute Kidney Injury and Renal Recovery following Cardiac Surgery
por: Meersch, Melanie, et al.
Publicado: (2014) -
Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury
por: Joannidis, Michael, et al.
Publicado: (2019) -
Urinary TIMP-2 and IGFBP7 elevate early in critically ill postoperative patients that develop AKI
por: Honore, P, et al.
Publicado: (2015)